# US 2026/0150836 A1 · Deuterium-labelled cannalactone synthesis and use for the dosage of cannalactone in all tissues or exudates of living plants or organisms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0150836 A1
- Document ID: US20260150836A1
- Status: Published application
- Kind: A1
- Application number: 19/256,798
- Filed: 2025-07-01
- Published: 2026-06-04
- Earliest claimed: 2024-07-01
- Applicants: Centre National De La Recherche Scientifique (Cnrs); Universite Paris-Saclay; Nantes Universite; Hemp It Adn
- Inventors: François Didier BOYER; Jean Bernard POUVREAU; Alexandre MACIUK; Suzanne DAIGNAN FORNIER DE LACHAUX; Fabienne MATHIS
- Web page: https://patentgrep.com/patent/US20260150836A1

## CPC

- A01N 43/08: with oxygen as the ring hetero atom
- C07D 307/46: Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
- C07B 59/002: {Heterocyclic compounds}
- C07D 307/58: One oxygen atom, e.g. butenolide
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to the chemical synthesis of cannalactone, an adaptation of this synthesis leading to deuterium labeling of cannalactone, as well as the use of deuterium-labeled cannalactone to perform the dosage of natural cannalactone of the exudates or tissues of the hemp plant.

## Claims

### Claim 1

A deuterium-labeled cannalactone, wherein the deuterium-labeled cannalactone corresponds to the general Formula (1):
wherein:
R1 denotes a hydrogen atom H or a deuterium atom D, —R2 denotes the methyl radical CH3 or the trisubstituted deuterated methyl radical CD3,
at least one of R1 and R2 being deuterated.

### Claim 2 (depends on 1)

The deuterium-labeled cannalactone according to claim 1,
wherein: —R1 denotes H, and
R2 denotes CD3.

### Claim 3 (depends on 1)

The deuterium-labeled cannalactone according to claim 1,
wherein: —R1 denotes D, and
R2 denotes CH3.

### Claim 4 (depends on 1)

The deuterium-labeled cannalactone according to claim 1,
wherein: —R1 denotes D, and
R2 denotes CD3.

### Claim 5

Method A method of synthesizing cannalactone, of general Formula (5)
the method comprising:
a reaction A) of coupling commercial β-cyclocitral with unbromofuran C4 of Formula (6)
to obtain an alcohol B20 of Formula (7)
a step B) of reducing the alcohol B20 of Formula (7), to obtain a mixture of diastereoisomers of the allyl alcohol, followed by a step of separating said diastereoisomers to retain the diastereoisomer (4R*, 6R*)-B21 of Formula (8)
a step C) of selectively epoxidizing the compound (4R*, 6R*)-B21 of Formula (8) to obtain the epoxy 4R*, 6R*)-cis-B22 of Formula (9)
a radical reaction D) of reduction and isomerization of the epoxide (4R*, 6R*)-cis-B22 of Formula (9), to obtain the tertiary alcohol (4R*, 8R*)-B1 of Formula (10)
a step E) of protecting the tertiary alcohol (4R*, 8R*)-B1 of Formula (10), to obtain the protected alcohol (4R*, 8R*)-B23 of Formula (11)
a step F) comprising formylation F1) of the compound (4R*, 8R*)-B23 of Formula (11) using alkyl formate corresponding to Formula (12)
then O-alkylation F2) of the aldehyde thus formed using compound D4 of Formula (13)
leading to obtaining the diastereoisomer mixture (4R*,6R*) B24 of Formula (14)
a step G) of deprotecting and separating the diastereoisomers of Formula (14), leading to the isolation of the cannalactone of Formula (5).

### Claim 6 (depends on 1)

The method for synthesizing a deuterium-labeled cannalactone as defined according to claim 1, comprising:
synthesizing a protected compound (4R*, 8R*)-B23 of Formula (11) by carrying out
a reaction A) of coupling commercial β-cyclocitral with unbromofuran C4 of Formula (6)
to obtain an alcohol B20 of Formula (7)
a step B) of reducing the alcohol B20 of Formula (7), to obtain a mixture of diastereoisomers of the allyl alcohol, followed by a step of separating said diastereoisomers to retain the
diastereoisomer (4R*, 6R*)-B21 of Formula (8)
a step C) of selectively epoxidizing the compound (4R*, 6R*)-B21 of Formula (8) to obtain the epoxy 4R*, 6R*)-cis-B22 of Formula
(9)
a radical reaction D) of reduction and isomerization of the epoxide (4R*, 6R*)-cis-B22 of Formula (9), to obtain the tertiary alcohol (4R*, 8R*)-B1 of Formula (10)
a step E) of protecting the tertiary alcohol (4R*, 8R*)-B1 of Formula (10), to obtain the protected alcohol (4R*, 8R*)-B23 of Formula (11)
a step F) comprising formylation F1) of the compound (4R*, 8R*)-B23 of Formula (11) using the ethyl formate corresponding to Formula (12)
or
using the deuterated alkyl formate corresponding to Formula (15)
then O-alkylation of the aldehyde thus formed using compound D4 of Formula (13)
or using the deuterated compound D4 of Formula
at least one of the organic compound functionalized by a formyl group or the compound D4 being deuterated,
to obtain a mixture of deuterated diastereoisomers (4R*,6R*) B24 of
with
R1 denoting a hydrogen atom H or a deuterium atom D, and
R2 denotes a methyl group (CH3) or a methyl group where the hydrogens have been replaced with deuterium atoms (CD3);
a step G) of deprotecting and separating the diastereoisomers, leading to the isolation of a deuterium-labeled cannalactone of Formula (1).

### Claim 7 (depends on 6)

The method according to claim 6, wherein:
formylation F1) is made of alkyl formate corresponding to Formula (12); and
the O-alkylation F2) of the aldehyde after formylation F1) is carried out using compound D4 of Formula 16.

### Claim 8 (depends on 6)

The method according to claim 6, wherein:
formylation F1) is performed using the deuterated alkyl formate corresponding to Formula (15); and
the O-alkylation F2) of the aldehyde after formylation F1) is carried out using compound D4 of Formula (13).

### Claim 9 (depends on 6)

The method according to claim 6, wherein:
formylation F1) is performed using the organic compound functionalized by a formyl group corresponding to Formula (15); and
the O-alkylation F2) of the aldehyde after formylation F1) is carried out using compound D4 of Formula (16).

### Claim 10 (depends on 1)

A method comprising utilizing the deuterium-labeled cannalactone as defined according to claim 1, to perform the dosage of the cannalactone in any tissue or exudates of living plants or organisms.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the method is carried out to perform the dosage of natural cannalactone of the exudates or tissues of the hemp plant by liquid chromatography coupled with mass spectrometry.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the tissue or exudates are exudates or tissues of the hemp plant.
